References
- Organization WH. Global report on psoriasis. World Health Organization; s2016. [accessed on 2019 May 4]. Available from: https://apps.who.int/iris/handle/10665/204417.
- Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2008;58:826–850.
- Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029–1072.
- Augustin M, Langenbruch A, Gutknecht M, et al. Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. Br J Dermatol. 2018;179:1385–1391.
- Carrascosa J-M, Jacobs I, Petersel D, et al. Biosimilar drugs for psoriasis: principles, present, and near future. Dermatol Ther. 2018;8:173–194.
- Patent expiry dates for biologicals: 2017 update - GaBI journal [WWW Document]. [accessed on 2019 May 4]. Available from: http://gabi-journal.net/patent-expiry-dates-for-biologicals-2017-update.html
- Cohen AD, Wu JJ, Puig L, et al. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. Br J Dermatol. 2017;177:1495–1502.
- FDA approves 19th biosimilar, 2nd for enbrel [WWW Document]. [accessed on 2019 May 4]. Available from: https://www.raps.org/news-and-articles/news-articles/2019/4/fda-approves-19th-biosimilar-2nd-for-enbrel
- biopharma-reporter.com. Biosimilars in the US: rising applications and approval rates [WWW Document]. Biopharma-Reportercom. [accessed on 2019 May 4]. Available from: https://www.biopharma-reporter.com/Article/2019/01/11/Biosimilar-applications-and-approvals-increase-in-the-US
- Azevedo V, Hassett B, Fonseca JE, et al. Differentiating biosimilarity and comparability in biotherapeutics. Clin Rheumatol. 2016;35:2877–2886.
- Anonymous. Biosimilar medicines: overview [WWW Document]. European Medicines Agency. 2018. [accessed on 2019 May 4]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview.
- Center for Drug Evaluation and Research, FDA. Scientific considerations in demonstrating biosimilarity to a reference product [WWW Document]. 2019. [accessed on 2019 May 4]. Available from: URL/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product.
- Blauvelt A, Cohen AD, Puig L, et al. Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. Br J Dermatol. 2016;174:282–286.
- Gerdes S, Mrowietz U, Augustin M, et al. Biosimilars in dermatology - theory becomes reality. J Dtsch Dermatol Ges. 2018;16:150–160.
- WHO | Similar biotherapeutic products [WWW Document]. WHO. [accessed on 2019 May 4]. Available from: http://www.who.int/biologicals/biotherapeutics/similar_biotherapeutic_products/en/.
- Anonymous. Inflectra [WWW Document]. European Medicines Agency. 2018. [accessed on 2019 May 4]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra
- Anonymous. Remsima [WWW Document]. European Medicines Agency. 2018 [accessed on 2019 May 4] Availble from: https://www.ema.europa.eu/en/medicines/human/EPAR/remsima
- Research C for DE and biosimilar product information. FDA 2019. [accessed on 2019 May 4]. URL/drugs/biosimilars/biosimilar-product-information
- Anonymous. Flixabi [WWW Document]. European Medicines Agency. 2018 [accessed on 2019 May 4]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/flixabi
- Drug Approval Package: Renflexis (infliximab-abda) [WWW Document]. [accessed on 2019 May 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761054Orig1s000TOC.cfm
- Drug approval package: ixifi (infliximab-qbtx) [WWW Document] .[accessed on 2019 May 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761072Orig1s000TOC.cfm
- Anonymous. Benepali [WWW Document]. European Medicines Agency. 2018 [accessed on 2019 May 4]. Availble from: https://www.ema.europa.eu/en/medicines/human/EPAR/benepali
- Anonymous. Erelzi [WWW Document]. European Medicines Agency. 2018 Availble from [accessed on 2019 May 4]. Availble form: https://www.ema.europa.eu/en/medicines/human/EPAR/erelzi
- Anonymous. Amgevita [WWW Document]. European Medicines Agency. 2018 [accessed on 2019 May 4]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/amgevita
- Anonymous. Solymbic [WWW Document]. European Medicines Agency. 2018 [accessed on 2019 May 4]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/solymbic.
- Anonymous. Imraldi [WWW Document]. European Medicines Agency. 2018 [accessed on 2019 May 4] Available from https://www.ema.europa.eu/en/medicines/human/EPAR/imraldi
- Anonymous. Cyltezo [WWW Document]. European Medicines Agency 2018. [accessed on 2019 May 4] Available from https://www.ema.europa.eu/en/medicines/human/EPAR/cyltezo
- Anonymous. Hyrimoz [WWW Document]. European Medicines Agency. 2018. [accessed on 2019 May 4] Available from https://www.ema.europa.eu/en/medicines/human/EPAR/hyrimoz
- Anonymous. Halimatoz [WWW Document]. European Medicines Agency. 2018. [accessed on 2019 May 4]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/halimatoz
- Anonymous. Hefiya [WWW Document]. European Medicines Agency. 2018. [accessed on 2019 May 4]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/hefiya
- Anonymous. Hulio [WWW Document]. European Medicines Agency. 2018. [accessed on 2019 May 4]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/hulio
- DIMITROVA EK. Idacio [WWW Document]. European Medicines Agency. 2019. [accessed on 2019 May 4]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/idacio
- DIMITROVA EK. Kromeya [WWW Document]. European Medicines Agency. 2019. [accessed on 2019 May 4]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kromeya
- Strand V, Girolomoni G, Schiestl M, et al. The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar. Curr Med Res Opin. 2017;33:993–1003.
- Hofmann H-P, Kronthaler U, Fritsch C, et al. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)). Expert Opin Biol Ther. 2016;16:1185–1195.
- Griffiths CEM, Thaçi D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176:928–938.
- Gerdes S, Thaçi D, Griffiths CEM, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol JEADV. 2018;32:420–427.
- Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76:1093–1102.
- Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;177:1562–1574.
- Blauvelt A, Lacour J-P, Fowler JF, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179:623–631.
- Efficacy, Safety and Immunogenicity of BI 695501 versus humira® in patients with moderate to severe chronic plaque psoriasis - study results - ClinicalTrials.gov [WWW Document]. [accessed on 2019 May 4]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02850965
- The VOLTAIRE-X trial looks at the effect of switching between humira® and BI 695501 in patients with plaque . - full text view psoriasis- ClinicalTrials.gov [WWW Document]. [accessed on 2019 May 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT03210259
- MSB11022 in moderate to severe chronic plaque psoriasis - study results - ClinicalTrials.gov [WWW Document]. [accessed on 2019 May 4]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02660580
- Blauvelt A, Puig L, Chimenti S, et al. Biosimilars for psoriasis: clinical studies to determine similarity. Br J Dermatol. 2017;177:23–33.
- AbbVie signs another licensing deal for adalimumab biosimilar/pharma news/home - GaBI onlineGenerics and Biosimilars Initiative [WWW Document] [accessed on 2019 May 4]. Available from: http://www.gabionline.net/Pharma-News/AbbVie-signs-another-licensing-deal-for-adalimumab-biosimilar
- Anonymous. Humira [WWW Document]. European Medicines Agency. 2018. [accessed on 2019 May 4]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/humira
- Mielke J, Woehling H, Jones B. Longitudinal assessment of the impact of multiple switches between a biosimilar and its reference product on efficacy parameters. Pharm Stat. 2018;17:231–247.
- Boone NW, Liu L, Romberg-Camps MJ, et al. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol. 2018;74:655–661.
- Megna M, Balato A, Napolitano M, et al. Psoriatic disease treatment nowadays: unmet needs among the ‘jungle of biologic drugs and small molecules’. Clin Rheumatol. 2018;37:1739–1741.